the aid library

LIST OPTIONS

Filter

5760

Sort by:

Direction:

Download (109)

View PDF (648)

How Twitter therapists are helping bring mental health care to Nigeria

Oluwatosin Adeshokan (2019) C2

DM for Care In northeastern Nigeria—“Boko Haram’s den”—at least 3 in 10 people suffer from untreated mental illness. Despite high suicide rates and risks of radicalization, care is reserved for treating substance use or disorders like schizophrenia. Nonprofits like NEEM Foundation a... more

Download (175)

View PDF (378)

Child labour report 2017 - The Neglected Link: effects of climate change and environmental degradation on child labour

Lisa Myers, Laura Theytaz-Bergman Terre des hommes (2017) C1

Over half a billion children are living in areas with extremely high levels of floods and nearly 160 million children live in areas of high or extremely high droughts. The World Health Organisation (WHO) estimates that 26% of the annual 6.6 million deaths of children under five are linked to environ... more

Download (358)

View PDF (938)

Risk Communication and Community Engagement Considerations: Ebola Response in Democratic Republic of the Congo

World Health Organization WHO (2018) C_WHO

Overview: Risk communication and community engagement are essential for any disease outbreak response. This is particularly critical during outbreaks of Ebola which may create fear in the public and frontline responders alike due to severe presentation of symptoms, misunderstanding of the causes of ... more

Download (133)

View PDF (245)

NCDs and climate change: Shared opportunities for action

NCD Alliance (2016) CC

The policy brief focuses on four key areas for intervention - air pollution, energy, transport and food systems. Air pollution causes 7 million deaths annually, and is a leading cause of both NCDs and climate change, thus all interventions to reduce air pollution have a positive impact on both human... more

Download (89)

View PDF (680)

Clinical Course and Outcome of Human Monkeypox in Nigeria

Ogoina, D.; Iroezindu, M.; Izibewule, J.H. et al. (2020) CC

In a retrospective review of hospital records of 40 human monkeypox cases from Nigeria, the majority developed fever and self-limiting vesiculopustular skin eruptions. Five deaths were reported. Compared to human immunodeficiency virus (HIV)–negative cases, HIV type 1–coinfected cases had more ... more

Download (94)

View PDF (182)

Tuberculosis in Brazil: the impact of the COVID-19 pandemic

Fernandes Maia, C.M.; Barbosa Martelli, D. R.; Mendes L. da Silveira, D. M.; et al. Sociedade Brasileira de Pneumologia e Tisiologia (2022) CC

J Bras Pneumol. 2022;48(2):e20220082 The spread of Severe Acute Respiratory Syndrome - Coronavirus 2 (SARS-CoV-2) continues to progress, causing damage in several countries of the world due to its rapid transmissibility and significant mortality rates, despite government measures to contain its tra... more

Download (83)

View PDF (143)

An integrated, Sustainable Framework to Elimination of Communicable Diseases in the Americas. Concept Note

Pan American Health Organisation (PAHO) (2019) C_WHO

The objective of this concept note and the framework it outlines is the elimination of a group of CDs and the negative health effects they generate, which together create a tangible burden on affected individuals, their families and communities, and on health care systems throughout the Region. Thou... more

Download (70)

View PDF (314)

Visceral leishmaniasis East Africa

World Health Organization WHO (2023) C_WHO

Visceral leishmaniasis is an important disease in East Africa where recurrent outbreaks occur. Leishmania-HIV coinfected people have high chance of developing the full-blown clinical disease, and high relapse and mortality rates. Poverty, malnutrition and population movements in endemic areas increa... more

Download (278)

View PDF (363)

User manual for WHO cervical cancer prevention and control costing tool: HPV vaccination module (‎C4P-HPV tool)

World Health Organisation (WHO) (2023) C_WHO

Cervical cancer is the fourth most common cancer in women worldwide in 2018, with 570,000 new cases and 311,000 deaths occurring annually.T he highest incidence rates are in Southern Africa, Eastern Africa, SubSaharan Africa, Western Africa, Melanesia, and Middle Africa . It also ranks as the leadin... more

Download (195)

View PDF (151)

Global Accelerated Action for the Health of Adolescents (AA-HA!): guidance to support country implementation, second edition.

World Health Organization WHO (2023) C_WHO

The World Health Organization (WHO) is releasing the second edition of its Global Accelerated Action for the Health of Adolescents (AA-HA!) guidance. The document aims to equip governments to respond to the health and well-being challenges, opportunities and needs of adolescents. The guidance pro... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (21)

View PDF (26)

Challenges in management and prevention of ischemic heart disease in low socioeconomic status people in LLMICs

Gupta, R.; Yusuf, S. BMC Medicine (2019) CC

Cardiovascular diseases, principally ischemic heart disease (IHD), are the most important cause of death and disability in the majority of low- and lower-middle-income countries (LLMICs). In these countries, IHD mortality rates are significantly greater in individuals of a low socioeconomic status (... more

Download (26)

View PDF (20)

Cardiovascular diseases in Africa in the twenty-first century: Gaps and priorities going forward

Minja, N.W.; Nakagaayi, D.; Aliku, T. et al. Frontiers in Cardiovascular Medicine (2022) CC

In 2015, the United Nations set important targets to reduce premature cardiovascular disease (CVD) deaths by 33% by 2030. Africa disproportionately bears the brunt of CVD burden and has one of the highest risks of dying from non-communicable diseases (NCDs) worldwide. There is currently an epide...miological transition on the continent, where NCDs is projected to outpace communicable diseases within the current decade. Unchecked increases in CVD risk factors have contributed to the growing burden of three major CVDs—hypertension, cardiomyopathies, and atherosclerotic diseasesleading to devastating rates of stroke and heart failure. The highest age standardized disability-adjusted life years (DALYs) due to hypertensive heart disease (HHD) were recorded in Africa. The contributory causes of heart failure are changing—whilst HHD and cardiomyopathies still dominate, ischemic heart disease is rapidly becoming a significant contributor, whilst rheumatic heart disease (RHD) has shown a gradual decline. In a continent where health systems are traditionally geared toward addressing communicable diseases, several gaps exist to adequately meet the growing demand imposed by CVDs. Among these, high-quality research to inform interventions, underfunded health systems with high out-of-pocket costs, limited accessibility and affordability of essential medicines, CVD preventive services, and skill shortages. Overall, the African continent progress toward a third reduction in premature mortality come 2030 is lagging behind. More can be done in the arena of effective policy implementation for risk factor reduction and CVD prevention, increasing health financing and focusing on strengthening primary health care services for prevention and treatment of CVDs, whilst ensuring availability and affordability of quality medicines. Further, investing in systematic country data collection and research outputs will improve the accuracy of the burden of disease data and inform policy adoption on interventions. This review summarizes the current CVD burden, important gaps in cardiovascular medicine in Africa, and further highlights priority areas where efforts could be intensified in the next decade with potential to improve the current rate of progress toward achieving a 33% reduction in CVD mortality. more

Download (9)

View PDF (8)

Burden of Peripheral Artery Disease and Its Attributable Risk Factors in 204 Countries and Territories From 1990 to 2019

Lin, J.; Chen, Y.; Jiang, N. et al. Frontiers in Cardiovascular Medicine (2022) CC

Background: Data on burden of peripheral artery disease (PAD) and its attributable risk factors are valuable for policymaking. We aimed to estimate the burden and risk factors for PAD from 1990 to 2019. Methods: We extracted the data on prevalence, incidence, death, years lived with disability (YLD... more

Download (20)

View PDF (15)

Can we prevent cardiovascular diseases in low- and middle-income countries?

Lenfant, C. Bulletin of the World Health Organization (2001) C_WHO

The article "Can we prevent cardiovascular diseases in low- and middle-income countries?" by Claude Lenfant discusses the growing threat of cardiovascular diseases (CVDs) in developing countries. It highlights that while CVD is already the leading cause of death globally, low- and middle-income coun... more

Download (9)

View PDF (9)

Surveillance of NCDs

World Health Organization WHO; Eastern Mediterranean Region World Health Organization (WHO) (2024) C_WHO

The WHO Eastern Mediterranean Region's Noncommunicable Diseases (NCD) Data and Statistics page offers comprehensive information on NCD surveillance, including mortality rates, morbidity, and risk factor exposures. It emphasizes the importance of monitoring NCD trends to inform prevention and control... more

Download (7)

View PDF (7)

Maladies non transmissibles 2024

World Health Organization WHO; Eastern Mediterranean Region World Health Organization (WHO) (2024) C_WHO

Download (12)

View PDF (19)

Surveillance of NCDs - arabic version

World Health Organization WHO; Eastern Mediterranean Region World Health Organization (WHO) (2024) C_WHO

Download (7)

View PDF (8)

The silent epidemic of COPD in Africa 2015

Salvi, S. The Lancet Global Health (2015) CC2

The article from The Lancet Global Health discusses the "silent epidemic" of chronic obstructive pulmonary disease (COPD) in Africa, emphasizing its status as an under-recognized yet significant health issue. Although COPD is the third leading cause of death globally, it remains largely overlooked i... more

Download (30)

View PDF (85)

Asthma management in low and middle income countries: case for change

Mortimer, K.; Reddel, H. K.; Pitrez, P. M.; et al. (2022) CC2

Asthma is the most common noncommunicable disease in children, and among the most common in adults. According to the most recent estimates from the Global Asthma Network Phase I study, around one in 10 children and adults have symptoms of asthma and one in 20 school-aged children have severe asthma ... more